NASDAQ Stock Exchange News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 1233,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "0ca9fab4-fe5e-4e96-b990-c004a2d6ac6f",
"title": "Vision Marine Technologies Files Patent for Advanced System Communication Encryption in E-Motion Powertrain By Investing.com",
"description": "Vision Marine Technologies Files Patent for Advanced System Communication Encryption in E-Motion Powertrain",
"keywords": "",
"snippet": "BOISBRIAND, QC / ACCESSWIRE / April 26, 2024 / Vision Marine Technologies Inc. (the \"Company\"), a pioneer in electric propulsion innovation, is pleased to annou...",
"url": "https://www.investing.com/news/press-releases/vision-marine-technologies-files-patent-for-advanced-system-communication-encryption-in-emotion-powertrain-93CH-3400545",
"image_url": "https://i-invdn-com.investing.com/news/international_newspapers_69x52._800x533_L_1419494241.jpg",
"language": "en",
"published_at": "2024-04-26T11:40:06.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "VMAR",
"name": "Vision Marine Technologies Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 97.694885,
"sentiment_score": 0.4723,
"highlights": [
{
"highlight": "BOISBRIAND, QC / ACCESSWIRE / April 26, 2024 / <em>Vision</em> <em>Marine</em> <em>Technologies</em> <em>Inc</em>. (the \"Company\"), a pioneer in electric propulsion innovation, is pleased to announce the patent filing for its cutting-edge Communication Cryptographic System technology, integral to the E-Motion™ Electric Powertrain components on April 24, 2024.",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "\"Our commitment to innovation extends beyond performance enhancements to include significant advancements in security and integrity of our systems,\" said Alexandre Mongeon, CEO of <em>Vision</em> <em>Marine</em> <em>Technologies</em> <em>Inc</em>.",
"sentiment": 0.8885,
"highlighted_in": "main_text"
},
{
"highlight": "See disclosureor\n\n\"Once we secure this patent, it will mark a pivotal moment for our industry, establishing a new benchmark for the secure operation of advanced marine propulsion systems in an increasingly digital world,\" remarked Xavier Montagne, Chief Technology Officer at <em>Vision</em> <em>Marine</em> <em>Technologies</em> <em>Inc</em>.",
"sentiment": 0.7003,
"highlighted_in": "main_text"
},
{
"highlight": "Resignation of Patrick Bobby as board member of <em>Vision</em> <em>Marine</em> <em>Technologies</em>\n\nThe Company announces the resignation of Mr. Patrick Bobby as a member of its Board of Directors and as its Head of Performance & Special Projects, effective April 22, 2024. Mr.",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Vision</em> <em>Marine</em> <em>Technologies</em> respects Mr. Bobby's decision and is deeply grateful for his years of dedication, insight, and leadership that have significantly contributed to shaping the future of the boating industry. The board and the entire team at Vision Marine wish Mr. Bobby the very best in his future endeavors.",
"sentiment": 0.9291,
"highlighted_in": "main_text"
},
{
"highlight": "See disclosureor\n\nAbout <em>Vision</em> <em>Marine</em> <em>Technologies</em>\n\n<em>Vision</em> <em>Marine</em> <em>Technologies</em>, <em>Inc</em>. (<em>NASDAQ:VMAR</em>) epitomizes the marine industry's shift towards electric propulsion, offering the pioneering E-Motion™ outboard powertrain system.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Investor relations and Company Contact:\n\nBruce Nurse\n\n(303) 919-2913\n\[email protected]\n\nSOURCE: <em>Vision</em> <em>Marine</em> <em>Technologies</em> <em>Inc</em>",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Vision</em> <em>Marine</em> <em>Technologies</em> Files Patent for Advanced System Communication Encryption in E-Motion Powertrain By Investing.com",
"sentiment": 0.25,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "85d8b094-7013-45f5-927b-c15cf8d141d3",
"title": "OptimizeRx Provides Business Update and Sets First Quarter 2024 Conference Call for May 14, 2024 at 4:30 p.m. ET By Investing.com",
"description": "OptimizeRx Provides Business Update and Sets First Quarter 2024 Conference Call for May 14, 2024 at 4:30 p.m. ET",
"keywords": "",
"snippet": "1Q24 revenue expected to grow over 40% year-over-year and come in between $18.5 - $19.2 million\n\n\n\nFirst quarter revenue and adjusted EBITDA to come in ahead of...",
"url": "https://www.investing.com/news/press-releases/optimizerx-provides-business-update-and-sets-first-quarter-2024-conference-call-for-may-14-2024-at-430-pm-et-93CH-3400546",
"image_url": "https://i-invdn-com.investing.com/news/news_six_pile_69x52._800x533_L_1419494215.jpg",
"language": "en",
"published_at": "2024-04-26T11:40:05.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "OPRX",
"name": "OptimizeRx Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 51.505264,
"sentiment_score": 0.255073,
"highlights": [
{
"highlight": "., April 26, 2024 (GLOBE NEWSWIRE) -- <em>OptimizeRx</em> (NASDAQ: ) Corp.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "(the Company) (<em>Nasdaq</em>: <em>OPRX</em>), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, is providing a business update for 2024 and is preannouncing preliminary, unaudited results for select financials for the first quarter of 2024.",
"sentiment": 0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "Steve Silvestro, <em>OptimizeRx</em> President commented, The momentum from the fourth quarter has carried into the first quarter of 2024 with the signing of 9 new DAAP deals.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Our commercial integration strategy between <em>OptimizeRx</em> and Medicx is also progressing ahead of our expectations, with numerous new cross-sell opportunities in late-stage negotiations. The integration of the two businesses is ahead of schedule and we are optimistic about our performance.",
"sentiment": 0.5994,
"highlighted_in": "main_text"
},
{
"highlight": "See disclosureor\n\nEarnings Call\n\n<em>OptimizeRx</em> will hold a conference call on Tuesday, May 14, 2024 at 4:30 p.m. Eastern Time to discuss its results for the first quarter for the period ended March 31, 2024. The financial results will be issued in a press release prior to the call.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "A replay of the call will remain available for 12 months via the Investors section of the <em>OptimizeRx</em> website at http://www.optimizerx.com/investors.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>OptimizeRx</em>\n\n<em>OptimizeRx</em> provides best-in-class health technology that enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey.",
"sentiment": 0.5994,
"highlighted_in": "main_text"
},
{
"highlight": "Connecting over 2 million U.S. healthcare providers and millions of their patients through an intelligent technology platform embedded within a proprietary digital point-of-care network, as well as mass digital communication channels, <em>OptimizeRx</em> helps life sciences organizations engage and support their customers.",
"sentiment": 0.8957,
"highlighted_in": "main_text"
},
{
"highlight": "See disclosureor\n\n<em>OPTIMIZERX</em> <em>CORPORATION</em>\n\nRECONCILIATION of GAAP to NON-GAAP FINANCIAL MEASURES\n\n(UNAUDITED)\n\n$ in millions Three Months Ended\n\nMarch 31, 2024 Net loss $(8.2) “ $(7.0) Interest $1.5 “ $1.5 Taxes $1.0 “ $0.5 Depreciation and amortization $1.1 “ $1.0 Stock-based compensation $3.0 “ $2.7 Severance charges $0.4 “ $0.4 Acquisition expense",
"sentiment": 0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "$0.2 “ $0.2 Adjusted EBITDA $(1.0) “ $(0.7)\n\n<em>OptimizeRx</em> Contact\n\nAndy D'Silva, SVP Corporate Finance\n\[email protected]\n\nMedia Relations Contact\n\nDilma Bennett, Media Relations Manager\n\[email protected]\n\nInvestor Relations Contact\n\nAshley Robinson\n\nLifeSci Advisors, LLC\n\[email protected]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>OptimizeRx</em> Provides Business Update and Sets First Quarter 2024 Conference Call for May 14, 2024 at 4:30 p.m. ET By Investing.com",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "2589e3f0-1a6f-4aaa-ad93-89e64f0de33f",
"title": "Bitfarms Schedules First Quarter 2024 Conference Call on May 13, 2024",
"description": "TORONTO and BROSSARD, Québec, April 26, 2024 (GLOBE NEWSWIRE) -- Bitfarms Ltd. (NASDAQ/TSX: BITF), a global vertically integrated Bitcoin mining...",
"keywords": "Toronto Stock Exchange:BITF, Bitfarms Ltd., financial results",
"snippet": "TORONTO and BROSSARD, Québec, April 26, 2024 (GLOBE NEWSWIRE) -- Bitfarms Ltd. (NASDAQ/TSX: BITF), a global vertically integrated Bitcoin mining company, will ...",
"url": "https://www.globenewswire.com/news-release/2024/04/26/2870375/0/en/Bitfarms-Schedules-First-Quarter-2024-Conference-Call-on-May-13-2024.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/77800350-6d8c-4aad-86e2-3df4ecafa655",
"language": "en",
"published_at": "2024-04-26T11:00:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "BITF",
"name": "Bitfarms Ltd.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 61.72214,
"sentiment_score": 0,
"highlights": [
{
"highlight": "TORONTO and BROSSARD, Québec, April 26, 2024 (GLOBE NEWSWIRE) -- <em>Bitfarms</em> <em>Ltd</em>. (NASDAQ/TSX: <em>BITF</em>), a global vertically integrated Bitcoin mining company, will report its first quarter 2024 financial results on Monday May13, 2024, before the market opens. Management will host a conference call on the same day at 8:00 am EST.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Bitfarms</em> <em>Ltd</em>.\n\nFounded in 2017, Bitfarms is a global, Bitcoin mining company that contributes its computational power to one or more mining pools from which it receives payment in Bitcoin.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BFARF",
"name": "Bitfarms Ltd.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 44.711487,
"sentiment_score": 0,
"highlights": [
{
"highlight": "TORONTO and BROSSARD, Québec, April 26, 2024 (GLOBE NEWSWIRE) -- <em>Bitfarms</em> <em>Ltd</em>. (NASDAQ/TSX: BITF), a global vertically integrated Bitcoin mining company, will report its first quarter 2024 financial results on Monday May13, 2024, before the market opens. Management will host a conference call on the same day at 8:00 am EST.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Bitfarms</em> <em>Ltd</em>.\n\nFounded in 2017, Bitfarms is a global, Bitcoin mining company that contributes its computational power to one or more mining pools from which it receives payment in Bitcoin.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BITF.V",
"name": "Bitfarms Ltd.",
"exchange": null,
"exchange_long": null,
"country": "ca",
"type": "equity",
"industry": "Financial Services",
"match_score": 44.708115,
"sentiment_score": 0,
"highlights": [
{
"highlight": "TORONTO and BROSSARD, Québec, April 26, 2024 (GLOBE NEWSWIRE) -- <em>Bitfarms</em> <em>Ltd</em>. (NASDAQ/TSX: BITF), a global vertically integrated Bitcoin mining company, will report its first quarter 2024 financial results on Monday May13, 2024, before the market opens. Management will host a conference call on the same day at 8:00 am EST.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Bitfarms</em> <em>Ltd</em>.\n\nFounded in 2017, Bitfarms is a global, Bitcoin mining company that contributes its computational power to one or more mining pools from which it receives payment in Bitcoin.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "7f92115c-89ae-4b10-80f0-fbfff504c650",
"title": "Medigene AG reports Financial Results and Business Update for Q1 2024",
"description": "Planegg/Martinsried, April 26, 2024. Medigene AG , an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial...",
"keywords": "Markets",
"snippet": "Planegg/Martinsried, April 26, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the...",
"url": "https://www.marketscreener.com/quote/stock/MEDIGENE-AG-14120225/news/Medigene-AG-reports-Financial-Results-and-Business-Update-for-Q1-2024-46542710/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
"language": "en",
"published_at": "2024-04-26T07:00:07.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "MDGEF",
"name": "Medigene AG",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 102.31047,
"sentiment_score": 0.356591,
"highlights": [
{
"highlight": "<em>Medigene</em> <em>AG</em> (<em>Medigene</em> or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial results for the first quarter of 2024.",
"sentiment": 0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "\"During the first quarter of 2024, our focus remained on executing our strategic plan and advancing the development of our unique TCR-T therapies for solid tumors, such as our lead program MDG1015,\" said Selwyn Ho, CEO at <em>Medigene</em>.",
"sentiment": 0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "From a partnering perspective, the Company’s ongoing global strategic collaboration with BioNTech continues to make good progress and <em>Medigene</em> is working on a number of undisclosed targets. In January 2024, Regeneron Pharmaceuticals Inc.",
"sentiment": 0.7184,
"highlighted_in": "main_text"
},
{
"highlight": "Upon reaching the contractually agreed milestone for the IIT, <em>Medigene</em> anticipates receiving an additional milestone payment. As previously announced, <em>Medigene</em> and Hongsheng Sciences have mutually agreed to terminate the remaining framework agreement of the partnership.",
"sentiment": 0.802,
"highlighted_in": "main_text"
},
{
"highlight": "Those assets previously under this agreement have been returned to <em>Medigene</em> for potential expansion of its pipeline.\n\nSubsequent to the quarter, on April 23, 2024, the Company announced the launch of a capital raise with subscription rights as part of the Company’s near and medium-term financing strategy.",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Medigene</em> intends to use the gross proceeds of up to approximately EUR 5.9 million to fund its operating activities and to progress work for the clinical development of the Company’s lead program, MDG1015.",
"sentiment": -0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "Members of <em>Medigene</em> AG’s management and Supervisory Board will subscribe for new shares as part of the rights offering and the private placement. Within the framework of a backstop agreement, an investor has declared his commitment to <em>Medigene</em> to acquire unsubscribed new shares in an amount of up to EUR 3 million.",
"sentiment": 0.8481,
"highlighted_in": "main_text"
},
{
"highlight": "As such, healthy cells that did not express the tumor antigen (NY-ESO-1) were not targeted, irrespective of their PD-L1 expression and no signs of toxicity were seen in diverse healthy tissues in vitro.\n\n--- end of press release ---\n\nAbout <em>Medigene</em> <em>AG</em>\n\n<em>Medigene</em> <em>AG</em> (FSE: MDG1) is an immuno-oncology platform company dedicated to developing differentiated",
"sentiment": 0.7697,
"highlighted_in": "main_text"
},
{
"highlight": "For more information, please visit https://medigene.com/\n\nThis press release contains forward-looking statements representing the opinion of <em>Medigene</em> as of the date of this release. The actual results achieved by <em>Medigene</em> may differ significantly from the forward-looking statements made herein.",
"sentiment": 0.3774,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Medigene</em> is not bound to update any of these forward-looking statements. <em>Medigene</em>® is a registered trademark of <em>Medigene</em> <em>AG</em>. This trademark may be owned or licensed in select locations only.\n\n<em>Medigene</em> <em>AG</em>\n\nPamela Keck\n\nPhone: +49 89 2000 3333 01\n\nE-mail: [email protected]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Medigene</em> <em>AG</em> reports Financial Results and Business Update for Q1 2024",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "REGN.MX",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 23.093803,
"sentiment_score": 0.3612,
"highlights": [
{
"highlight": "In January 2024, <em>Regeneron</em> <em>Pharmaceuticals</em> <em>Inc</em>. (Regeneron; formerly: 2seventy bio, Inc.) commenced patient enrollment in an investigator-initiated trial (IIT) in Greater China for the program utilizing Medigene's TCR targeting MAGE-A4.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0QGJ.L",
"name": "Medigene AG",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 102.22655,
"sentiment_score": 0.356591,
"highlights": [
{
"highlight": "<em>Medigene</em> <em>AG</em> (<em>Medigene</em> or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial results for the first quarter of 2024.",
"sentiment": 0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "\"During the first quarter of 2024, our focus remained on executing our strategic plan and advancing the development of our unique TCR-T therapies for solid tumors, such as our lead program MDG1015,\" said Selwyn Ho, CEO at <em>Medigene</em>.",
"sentiment": 0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "From a partnering perspective, the Company’s ongoing global strategic collaboration with BioNTech continues to make good progress and <em>Medigene</em> is working on a number of undisclosed targets. In January 2024, Regeneron Pharmaceuticals Inc.",
"sentiment": 0.7184,
"highlighted_in": "main_text"
},
{
"highlight": "Upon reaching the contractually agreed milestone for the IIT, <em>Medigene</em> anticipates receiving an additional milestone payment. As previously announced, <em>Medigene</em> and Hongsheng Sciences have mutually agreed to terminate the remaining framework agreement of the partnership.",
"sentiment": 0.802,
"highlighted_in": "main_text"
},
{
"highlight": "Those assets previously under this agreement have been returned to <em>Medigene</em> for potential expansion of its pipeline.\n\nSubsequent to the quarter, on April 23, 2024, the Company announced the launch of a capital raise with subscription rights as part of the Company’s near and medium-term financing strategy.",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Medigene</em> intends to use the gross proceeds of up to approximately EUR 5.9 million to fund its operating activities and to progress work for the clinical development of the Company’s lead program, MDG1015.",
"sentiment": -0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "Members of <em>Medigene</em> AG’s management and Supervisory Board will subscribe for new shares as part of the rights offering and the private placement. Within the framework of a backstop agreement, an investor has declared his commitment to <em>Medigene</em> to acquire unsubscribed new shares in an amount of up to EUR 3 million.",
"sentiment": 0.8481,
"highlighted_in": "main_text"
},
{
"highlight": "As such, healthy cells that did not express the tumor antigen (NY-ESO-1) were not targeted, irrespective of their PD-L1 expression and no signs of toxicity were seen in diverse healthy tissues in vitro.\n\n--- end of press release ---\n\nAbout <em>Medigene</em> <em>AG</em>\n\n<em>Medigene</em> <em>AG</em> (FSE: MDG1) is an immuno-oncology platform company dedicated to developing differentiated",
"sentiment": 0.7697,
"highlighted_in": "main_text"
},
{
"highlight": "For more information, please visit https://medigene.com/\n\nThis press release contains forward-looking statements representing the opinion of <em>Medigene</em> as of the date of this release. The actual results achieved by <em>Medigene</em> may differ significantly from the forward-looking statements made herein.",
"sentiment": 0.3774,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Medigene</em> is not bound to update any of these forward-looking statements. <em>Medigene</em>® is a registered trademark of <em>Medigene</em> <em>AG</em>. This trademark may be owned or licensed in select locations only.\n\n<em>Medigene</em> <em>AG</em>\n\nPamela Keck\n\nPhone: +49 89 2000 3333 01\n\nE-mail: [email protected]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Medigene</em> <em>AG</em> reports Financial Results and Business Update for Q1 2024",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "0R2M.L",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 23.091549,
"sentiment_score": 0.3612,
"highlights": [
{
"highlight": "In January 2024, <em>Regeneron</em> <em>Pharmaceuticals</em> <em>Inc</em>. (Regeneron; formerly: 2seventy bio, Inc.) commenced patient enrollment in an investigator-initiated trial (IIT) in Greater China for the program utilizing Medigene's TCR targeting MAGE-A4.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "REGN34.SA",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 23.091192,
"sentiment_score": 0.3612,
"highlights": [
{
"highlight": "In January 2024, <em>Regeneron</em> <em>Pharmaceuticals</em> <em>Inc</em>. (Regeneron; formerly: 2seventy bio, Inc.) commenced patient enrollment in an investigator-initiated trial (IIT) in Greater China for the program utilizing Medigene's TCR targeting MAGE-A4.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "REGN",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 23.091078,
"sentiment_score": 0.3612,
"highlights": [
{
"highlight": "In January 2024, <em>Regeneron</em> <em>Pharmaceuticals</em> <em>Inc</em>. (Regeneron; formerly: 2seventy bio, Inc.) commenced patient enrollment in an investigator-initiated trial (IIT) in Greater China for the program utilizing Medigene's TCR targeting MAGE-A4.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MDG1.DE",
"name": "Medigene AG",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 101.98818,
"sentiment_score": 0.356591,
"highlights": [
{
"highlight": "<em>Medigene</em> <em>AG</em> (<em>Medigene</em> or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial results for the first quarter of 2024.",
"sentiment": 0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "\"During the first quarter of 2024, our focus remained on executing our strategic plan and advancing the development of our unique TCR-T therapies for solid tumors, such as our lead program MDG1015,\" said Selwyn Ho, CEO at <em>Medigene</em>.",
"sentiment": 0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "From a partnering perspective, the Company’s ongoing global strategic collaboration with BioNTech continues to make good progress and <em>Medigene</em> is working on a number of undisclosed targets. In January 2024, Regeneron Pharmaceuticals Inc.",
"sentiment": 0.7184,
"highlighted_in": "main_text"
},
{
"highlight": "Upon reaching the contractually agreed milestone for the IIT, <em>Medigene</em> anticipates receiving an additional milestone payment. As previously announced, <em>Medigene</em> and Hongsheng Sciences have mutually agreed to terminate the remaining framework agreement of the partnership.",
"sentiment": 0.802,
"highlighted_in": "main_text"
},
{
"highlight": "Those assets previously under this agreement have been returned to <em>Medigene</em> for potential expansion of its pipeline.\n\nSubsequent to the quarter, on April 23, 2024, the Company announced the launch of a capital raise with subscription rights as part of the Company’s near and medium-term financing strategy.",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Medigene</em> intends to use the gross proceeds of up to approximately EUR 5.9 million to fund its operating activities and to progress work for the clinical development of the Company’s lead program, MDG1015.",
"sentiment": -0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "Members of <em>Medigene</em> AG’s management and Supervisory Board will subscribe for new shares as part of the rights offering and the private placement. Within the framework of a backstop agreement, an investor has declared his commitment to <em>Medigene</em> to acquire unsubscribed new shares in an amount of up to EUR 3 million.",
"sentiment": 0.8481,
"highlighted_in": "main_text"
},
{
"highlight": "As such, healthy cells that did not express the tumor antigen (NY-ESO-1) were not targeted, irrespective of their PD-L1 expression and no signs of toxicity were seen in diverse healthy tissues in vitro.\n\n--- end of press release ---\n\nAbout <em>Medigene</em> <em>AG</em>\n\n<em>Medigene</em> <em>AG</em> (FSE: MDG1) is an immuno-oncology platform company dedicated to developing differentiated",
"sentiment": 0.7697,
"highlighted_in": "main_text"
},
{
"highlight": "For more information, please visit https://medigene.com/\n\nThis press release contains forward-looking statements representing the opinion of <em>Medigene</em> as of the date of this release. The actual results achieved by <em>Medigene</em> may differ significantly from the forward-looking statements made herein.",
"sentiment": 0.3774,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Medigene</em> is not bound to update any of these forward-looking statements. <em>Medigene</em>® is a registered trademark of <em>Medigene</em> <em>AG</em>. This trademark may be owned or licensed in select locations only.\n\n<em>Medigene</em> <em>AG</em>\n\nPamela Keck\n\nPhone: +49 89 2000 3333 01\n\nE-mail: [email protected]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Medigene</em> <em>AG</em> reports Financial Results and Business Update for Q1 2024",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "3a2b51c7-89ec-48ed-9714-3b5d1a4963dc",
"title": "Heritage Commerce Corp (HTBK) Misses Q1 Earnings Expectations, Sees Growth in Client Deposits",
"description": "Net Income: Reported $10.2 million for Q1 2024, falling short of the estimated $11.16 million.Earnings Per Share (EPS): Achieved $0.17 per average diluted comm",
"keywords": "GuruFocus, Article, News, GuruFocus Research, HTBK",
"snippet": "On April 25, 2024, Heritage Commerce Corp (HTBK, Financial) disclosed its first-quarter financial results through its 8-K filing, revealing a net income of $10....",
"url": "https://www.gurufocus.com/news/2419497/heritage-commerce-corp-htbk-misses-q1-earnings-expectations-sees-growth-in-client-deposits",
"image_url": "https://static.gurufocus.com/logos/0C00000B9S.png?5",
"language": "en",
"published_at": "2024-04-26T11:33:55.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "HTBK",
"name": "Heritage Commerce Corp",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 117.63425,
"sentiment_score": 0.481057,
"highlights": [
{
"highlight": "On April 25, 2024, <em>Heritage</em> <em>Commerce</em> <em>Corp</em> (HTBK, Financial) disclosed its first-quarter financial results through its 8-K filing, revealing a net income of $10.2 million, or $0.17 per average diluted common share. These figures fell short of analyst expectations, which had estimated earnings per share at $0.18 and net income at $11.16 million.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Heritage</em> <em>Commerce</em> <em>Corp</em> operates as a bank holding company through its subsidiary, Heritage Bank of Commerce, offering commercial banking services primarily to small and medium-sized businesses. The bank operates through two segments, Banking and Factoring, with the majority of its revenue derived from the Banking segment.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Financial Highlights and Strategic Achievements\n\nThe first quarter of 2024 saw <em>Heritage</em> <em>Commerce</em> <em>Corp</em> navigate through increased seasonal expenses such as payroll taxes and benefits, which are typical for this period.",
"sentiment": 0.5719,
"highlighted_in": "main_text"
},
{
"highlight": "Operational and Financial Metrics\n\nThe detailed financial metrics reveal a mixed picture of <em>Heritage</em> <em>Commerce</em> Corp's performance. The bank's total assets decreased by 5% year-over-year to $5.26 billion but showed a slight increase from the previous quarter.",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "Looking Forward\n\nDespite the challenges posed by increased costs and interest rate pressures, <em>Heritage</em> <em>Commerce</em> <em>Corp</em> remains optimistic about its future. The bank's strong credit quality, coupled with strategic recognition and a robust client base, positions it well for ongoing stability and growth.",
"sentiment": 0.9434,
"highlighted_in": "main_text"
},
{
"highlight": "For a detailed view of <em>Heritage</em> <em>Commerce</em> Corp's financial performance and strategic positioning, stakeholders and interested investors are encouraged to review the full 8-K filing.\n\nExplore the complete 8-K earnings release (here) from <em>Heritage</em> <em>Commerce</em> <em>Corp</em> for further details.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Heritage</em> <em>Commerce</em> <em>Corp</em> (HTBK) Misses Q1 Earnings Expectations, Sees Growth in Client Deposits",
"sentiment": 0.1779,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "09c247ec-bffd-42b7-9d91-c3e24593d7eb",
"title": "SPS Commerce Inc (SPSC) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and Strategic Acquisitions",
"description": "Q1 2024 Revenue: $149.6 million, up 19% year-over-yearRecurring Revenue Growth: 19% year-over-yearAdjusted EBITDA: $44.4 million, up 20% from $37 million in Q1",
"keywords": "GuruFocus, Article, News, GuruFocus Research, SPSC",
"snippet": "Release Date: April 25, 2024\n\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n\nQ & A Highlights\n\nQ: Can you...",
"url": "https://www.gurufocus.com/news/2419401/sps-commerce-inc-spsc-q1-2024-earnings-call-transcript-highlights-robust-growth-and-strategic-acquisitions",
"image_url": "https://static.gurufocus.com/logos/0C00004APQ.png?5",
"language": "en",
"published_at": "2024-04-26T07:38:23.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "SPSC",
"name": "SPS Commerce, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 119.32902,
"sentiment_score": 0.4689,
"highlights": [
{
"highlight": "A: Kimberly Nelson, CFO of <em>SPS</em> <em>Commerce</em>, explained that VISION 33 was already a partner, so there would be no significant change in the financials for 2024 due to the acquisition. The purchase price was nominal, and the acquisition is not expected to impact the financials significantly.",
"sentiment": 0.3254,
"highlighted_in": "main_text"
},
{
"highlight": "<em>SPS</em> <em>Commerce</em> <em>Inc</em> (SPSC) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and Strategic Acquisitions",
"sentiment": 0.6124,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "7a2489fc-a3e4-423f-8bac-23c669f52d33",
"title": "Chevron Corp (CVX) Reports Q1 2024 Earnings: A Close Call with Analyst Projections",
"description": "Earnings Per Share (EPS): Reported at $2.97, slightly above the estimated $2.87.Net Income: Reported at $5.5 billion, surpassing the estimate of $5.35 billion.",
"keywords": "GuruFocus, Article, News, GuruFocus Research, CVX",
"snippet": "Chevron Corp (CVX, Financial) released its 8-K filing on April 26, 2024, disclosing its financial results for the first quarter of 2024. The company reported ea...",
"url": "https://www.gurufocus.com/news/2419493/chevron-corp-cvx-reports-q1-2024-earnings-a-close-call-with-analyst-projections",
"image_url": "https://static.gurufocus.com/logos/0C000007BJ.png?5",
"language": "en",
"published_at": "2024-04-26T11:32:08.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "PDCE",
"name": "PDC Energy, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Energy",
"match_score": 29.274185,
"sentiment_score": 0.802,
"highlights": [
{
"highlight": "Operational Highlights and Strategic Achievements\n\nChevron's operational performance saw a significant boost with a 12% increase in worldwide production, largely attributed to the acquisition of <em>PDC</em> <em>Energy</em>, <em>Inc</em>. and robust activities in the Permian and Denver-Julesburg basins.",
"sentiment": 0.802,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "fe12df2b-8c5e-44a5-b97d-fcc04bb4b395",
"title": "Nifty Bank snaps 5-day winning streak; support seen at 48,000 next week: Experts",
"description": "The Nifty Bank fell nearly 300 points to close at 48,201 while the Nifty50 fell 150 points to close above 22,400 level.",
"keywords": "nifty bank index, nifty bank, bank stocks, bank stocks to buy, nifty news, stock market news",
"snippet": "\n\n\n\n(You can now subscribe to our\n\n(You can now subscribe to our ETMarkets WhatsApp channel\n\nThe Nifty Bank snapped a five-day winning streak on Friday to close...",
"url": "https://economictimes.indiatimes.com/markets/stocks/news/nifty-bank-snaps-5-day-winning-streak-support-seen-at-48000-next-week-experts/articleshow/109625727.cms",
"image_url": "https://img.etimg.com/thumb/msid-109625718,width-1200,height-630,imgsize-25842,overlay-etmarkets/photo.jpg",
"language": "en",
"published_at": "2024-04-26T11:22:48.000000Z",
"source": "economictimes.indiatimes.com",
"relevance_score": null,
"entities": [
{
"symbol": "FRBA",
"name": "First Bank",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 14.040252,
"sentiment_score": 0.66275,
"highlights": [
{
"highlight": "(You can now subscribe to our\n\n(You can now subscribe to our ETMarkets WhatsApp channel\n\nThe Nifty Bank snapped a five-day winning streak on Friday to close in the red tracking muted global cues.The Nifty Bank fell nearly 300 points to close at 48,201 while the Nifty50 fell 150 points to close above 22,400 level.PNB, Federal Bank and IDFC <em>First</em>",
"sentiment": 0.8316,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Bank</em> witnessed buying while selling was seen in SBI, ICICI Bank, AU Small Finance Bank and IndusInd Bank.The Nifty Bank managed to hold on to 48,000 in intraday trade which will now act as a crucial support for the index next week if the selling pressure continues.\"",
"sentiment": 0.4939,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "4d59ba68-f6b9-480b-b3d3-6aedb52de591",
"title": "Q1 2024 Business First Bancshares Inc Earnings Call Transcript",
"description": "Apr 25, 2024 / 09:00PM GMTOperator Thank you for standing by. My name is Mandeep, and I'll be your conference operator today. At this time, I would like to welc",
"keywords": "GuruFocus, Article, News, GuruFocus Research, NAS:BFST",
"snippet": "Apr 25, 2024 / 09:00PM GMT\n\nOperator\n\n\n\nThank you for standing by. My name is Mandeep, and I'll be your conference operator today. At this time, I would like to...",
"url": "https://www.gurufocus.com/news/2419490/q1-2024-business-first-bancshares-inc-earnings-call-transcript",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2024-04-26T11:13:14.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "BFST",
"name": "Business First Bancshares, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 156.71622,
"sentiment_score": 0.485,
"highlights": [
{
"highlight": "At this time, I would like to welcome everyone to the <em>Business</em> <em>First</em> <em>Bancshares</em> Q1 2024 earnings call. (Operator Instructions)\n\n\n\nI will now turn the conference over to Matt Sealey, SVP, Director of Corporate Strategy and FP&A. You may begin.",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "Matthew Sealy - <em>Business</em> <em>First</em> <em>Bancshares</em> <em>Inc</em> - Senior Vice President, Director of Corporate Strategy & FP&A\n\n\n\nThank you. Good afternoon, everyone. Thank you all for joining.",
"sentiment": 0.7845,
"highlighted_in": "main_text"
},
{
"highlight": "Q1 2024 <em>Business</em> <em>First</em> <em>Bancshares</em> <em>Inc</em> Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "4e327a79-56cd-4752-aee5-b9e0eaade3c3",
"title": "Nasdaq Composite Technical Analysis",
"description": "The surprisingly hot quarterly Core PCE couldn’t keep the Nasdaq Composite down. What’s next?",
"keywords": "Nasdaq Composite, Nasdaq Composite Technical Analysis",
"snippet": "Yesterday, the Nasdaq Composite opened lower following a selloff caused by surprisingly high Core PCE data in the US Q1 GDP report. The market started to fade t...",
"url": "https://www.forexlive.com/technical-analysis/nasdaq-composite-technical-analysis-20240426/",
"image_url": "https://images.forexlive.com/images/Nasdaq%20Composite%20Technical%20Analysis_id_56b404df-ad09-495b-8386-14e057408d4f_size975.jpg",
"language": "en",
"published_at": "2024-04-26T11:06:32.000000Z",
"source": "forexlive.com",
"relevance_score": null,
"entities": [
{
"symbol": "GOOGL",
"name": "Alphabet Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Communication Services",
"match_score": 38.583836,
"sentiment_score": 0.8402,
"highlights": [
{
"highlight": "Moreover, we should see a positive gap today as tech earnings after the close were much better than expected and some key stocks like <em>Alphabet</em> surged into new highs.",
"sentiment": 0.8402,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "3981eac3-bc0b-48f5-afd1-a21b96d6f100",
"title": "Identiv Sets First Quarter 2024 Earnings Call for Wednesday, May 8, 2024 at 5:00 PM EDT",
"description": "Identiv, Inc. , a global leader in digital security and identification in the Internet of Things , will hold a teleconference and webcast on Wednesday, May 8, 2024 at 5:00 PM EDT to discuss its...",
"keywords": "Markets",
"snippet": "Identiv, Inc. (NASDAQ: INVE), a global leader in digital security and identification in the Internet of Things (IoT), will hold a teleconference and webcast on ...",
"url": "https://www.marketscreener.com/quote/stock/IDENTIV-INC-16699862/news/Identiv-Sets-First-Quarter-2024-Earnings-Call-for-Wednesday-May-8-2024-at-5-00-PM-EDT-46545270/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
"language": "en",
"published_at": "2024-04-26T11:03:06.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "INVE",
"name": "Identiv, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 84.263954,
"sentiment_score": 0.051333,
"highlights": [
{
"highlight": "<em>Identiv</em>, <em>Inc</em>. (<em>NASDAQ</em>: <em>INVE</em>), a global leader in digital security and identification in the Internet of Things (IoT), will hold a teleconference and webcast on Wednesday, May 8, 2024 at 5:00 PM EDT to discuss its financial results for the first quarter ended March 31, 2024.",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Identiv</em>\n\n<em>Identiv</em>, <em>Inc</em>. is a global leader in digitally securing the physical world. Identiv’s platform encompasses RFID and NFC, cybersecurity, and the full spectrum of physical access, video, and audio security. For more information, visit identiv.com.",
"sentiment": -0.186,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Identiv</em> Sets First Quarter 2024 Earnings Call for Wednesday, May 8, 2024 at 5:00 PM EDT",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "a0bfca5e-921a-49ee-bb55-e65de7a85188",
"title": "US megacaps to lead stock rally until real rates bite, says BofA",
"description": "The US equity market will continue to rely on a handful of megacap stocks for direction until an uptick in real interest rates ignites recession fears, according to Bank of America Corp strategists.",
"keywords": "",
"snippet": "(April 26): The US equity market will continue to rely on a handful of megacap stocks for direction until an uptick in real interest rates ignites recession fea...",
"url": "https://theedgemalaysia.com/node/709547",
"image_url": "https://assets.theedgemarkets.com/nyse us stocks wall street 20240426_20240426190455_bloomberg.jpg",
"language": "en",
"published_at": "2024-04-26T11:03:04.000000Z",
"source": "theedgemarkets.com",
"relevance_score": null,
"entities": [
{
"symbol": "AAPL",
"name": "Apple Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 14.103539,
"sentiment_score": 0.6486,
"highlights": [
{
"highlight": "Despite a turbulent April, appetite for large cap growth stocks has shown no sign of abating, with the so-called Magnificent 7 — a group that includes Nvidia Corp, <em>Apple</em> <em>Inc</em> and Amazon.com Inc — maintaining a wide performance gap against the rest of the market since the start of the year.",
"sentiment": 0.6486,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AMZN",
"name": "Amazon.com, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 20.211731,
"sentiment_score": 0.6486,
"highlights": [
{
"highlight": "Despite a turbulent April, appetite for large cap growth stocks has shown no sign of abating, with the so-called Magnificent 7 — a group that includes Nvidia Corp, Apple Inc and <em>Amazon.com</em> <em>Inc</em> — maintaining a wide performance gap against the rest of the market since the start of the year.",
"sentiment": 0.6486,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GOOG",
"name": "Alphabet Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Communication Services",
"match_score": 11.775768,
"sentiment_score": 0.5106,
"highlights": [
{
"highlight": "Strong results from Microsoft Corp and <em>Alphabet</em> <em>Inc</em> on Thursday are expected to keep the big tech rally going.",
"sentiment": 0.5106,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GOOGL",
"name": "Alphabet Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Communication Services",
"match_score": 18.73553,
"sentiment_score": 0.5106,
"highlights": [
{
"highlight": "Strong results from Microsoft Corp and <em>Alphabet</em> <em>Inc</em> on Thursday are expected to keep the big tech rally going.",
"sentiment": 0.5106,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "edf81493-7e32-4a16-9918-357b3093304b",
"title": "BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates",
"description": "EQS-News: BB BIOTECH AG\n\n\n / Key word: Interim Report\n\n\n\n\n\nBB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates...",
"keywords": "Markets",
"snippet": "EQS-News: BB BIOTECH AG / Key word(s): Interim Report\n\nBB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on inter...",
"url": "https://www.marketscreener.com/quote/stock/BB-BIOTECH-AG-2975835/news/BB-Biotech-presents-solid-first-quarter-results-biotech-stock-market-impacted-by-shifting-views-on-46540083/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
"language": "en",
"published_at": "2024-04-26T05:02:09.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "ARGX",
"name": "argenx SE",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 13.336823,
"sentiment_score": 0.296,
"highlights": [
{
"highlight": "Composition of BB Biotech’s portfolio as at March 31, 2024\n\n(in % of securities, rounded values)\n\nIonis Pharmaceuticals 11.4% <em>Argenx</em> <em>SE</em> 9.7% Neurocrine Biosciences 9.0% Vertex Pharmaceuticals 7.7% Intra-Cellular Therapies 6.2% Moderna 5.8% Revolution Medicines 5.2% Macrogenics 4.7% Alnylam Pharmaceuticals 4.3% Incyte 3.9% Celldex Therapeutics 3.7% Agios",
"sentiment": 0.296,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GBIO",
"name": "Generation Bio Co.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 16.235317,
"sentiment_score": 0.519567,
"highlights": [
{
"highlight": "Further portfolio enhancements involved additions to Sage and <em>Generation</em> <em>Bio</em>, and profits from Crispr Therapeutics were reallocated to Beam Therapeutics.\n\nPortfolio milestones for the first quarter 2024\n\nBiotech markets remained volatile during the first quarter of 2024.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "Pharmaceuticals 3.7% Arvinas 3.1% Sage Therapeutics 2.7% Essa Pharma 2.1% Biohaven 2.0% Immunocore 2.0% Relay Therapeutics 1.6% Exelixis 1.4% Black Diamond Therapeutics 1.4% Crispr Therapeutics 1.3% Beam Therapeutics 1.3% Scholar Rock Holding 1.2% Fate Therapeutics 1.1% Esperion Therapeutics 0.9% Wave Life Sciences 0.8% Rivus Pharmaceuticals1) 0.6% <em>Generation</em>",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Bio</em> <em>Co</em>. 0.5% Annexon 0.5% Molecular Templates 0.1% Radius Health – CVR 0.0% Total securities CHF 2 822.2 mn Other assets CHF 5.8 mn Other payables CHF (354.0) mn Net Asset Value CHF 2 474.0 mn\n\n\n\n1) Unlisted company",
"sentiment": 0.7783,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ARGNF",
"name": "argenx SE",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 13.335537,
"sentiment_score": 0.296,
"highlights": [
{
"highlight": "Composition of BB Biotech’s portfolio as at March 31, 2024\n\n(in % of securities, rounded values)\n\nIonis Pharmaceuticals 11.4% <em>Argenx</em> <em>SE</em> 9.7% Neurocrine Biosciences 9.0% Vertex Pharmaceuticals 7.7% Intra-Cellular Therapies 6.2% Moderna 5.8% Revolution Medicines 5.2% Macrogenics 4.7% Alnylam Pharmaceuticals 4.3% Incyte 3.9% Celldex Therapeutics 3.7% Agios",
"sentiment": 0.296,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BBAGF",
"name": "BB Biotech AG",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 68.14903,
"sentiment_score": 0.41254,
"highlights": [
{
"highlight": "EQS-News: <em>BB</em> <em>BIOTECH</em> <em>AG</em> / Key word(s): Interim Report\n\n<em>BB</em> <em>Biotech</em> presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates\n\n\n\n26.04.2024 / 07:00 CET/CEST\n\nThe issuer is solely responsible for the content of this announcement.",
"sentiment": 0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "Media release as at April 26, 2024\n\nPortfolio of <em>BB</em> <em>Biotech</em> <em>AG</em> as at March 31, 2024\n\n<em>BB</em> <em>Biotech</em> presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates\n\nInvestor sentiment in the biotech space continues to be shaped by the general interest rate environment.",
"sentiment": 0.765,
"highlighted_in": "main_text"
},
{
"highlight": "Nevertheless, for <em>BB</em> <em>Biotech</em> investors, the first quarter of 2024 ended with a pleasing performance of 11.3% in CHF and 7.6% in EUR including the dividend payout of CHF 2.00 per share. The portfolio's total return (NAV) stood at 11.2% in CHF, 6.3% in EUR, and 3.8% in USD, which was slightly ahead of BB Biotech’s benchmark.",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "The <em>BB</em> <em>Biotech</em> share achieved a positive quarterly return of 11.3% in CHF and 7.6% in EUR, inclusive of a dividend payment of CHF 2.00 per share. The portfolio's total return was 11.2% in CHF, 6.3% in EUR, and 3.8% in USD, surpassing the NBI Index. The devaluation of the Swiss franc gave the portfolio a strong boost in the first quarter of 2024.",
"sentiment": 0.9186,
"highlighted_in": "main_text"
},
{
"highlight": "<em>BB</em> <em>Biotech</em> engaged in capital increases for Celldex and Esperion. Further portfolio enhancements involved additions to Sage and Generation Bio, and profits from Crispr Therapeutics were reallocated to Beam Therapeutics.\n\nPortfolio milestones for the first quarter 2024\n\nBiotech markets remained volatile during the first quarter of 2024.",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "Gallen, Switzerland, tel. +41 79 423 22 28\n\nThomas Egger, [email protected]\n\nwww.bbbiotech.com\n\nCompany profile\n\n<em>BB</em> <em>Biotech</em> <em>AG</em> is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss and German stock exchanges.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>BB</em> <em>Biotech</em> is one of the world’s largest investors in this sector. The competent Board of Directors with its long-standing experience set the investment strategy and guidelines. Investment decisions are taken by the experienced investment management team of Bellevue Asset Management AG based on their extensive investment research.",
"sentiment": 0.5859,
"highlighted_in": "main_text"
},
{
"highlight": "Such statements are based on the current expectations of <em>BB</em> <em>Biotech</em>, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, <em>BB</em> <em>Biotech</em> and its directors and officers accept no responsibility in that regard.",
"sentiment": -0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "All forward-looking statements included in this release are made only as of the date of this release and <em>BB</em> <em>Biotech</em> and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.",
"sentiment": -0.296,
"highlighted_in": "main_text"
},
{
"highlight": "<em>BB</em> <em>Biotech</em> presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates",
"sentiment": 0.5574,
"highlighted_in": "title"
}
]
},
{
"symbol": "BBZA.DE",
"name": "BB Biotech AG",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 68.14914,
"sentiment_score": 0.41254,
"highlights": [
{
"highlight": "EQS-News: <em>BB</em> <em>BIOTECH</em> <em>AG</em> / Key word(s): Interim Report\n\n<em>BB</em> <em>Biotech</em> presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates\n\n\n\n26.04.2024 / 07:00 CET/CEST\n\nThe issuer is solely responsible for the content of this announcement.",
"sentiment": 0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "Media release as at April 26, 2024\n\nPortfolio of <em>BB</em> <em>Biotech</em> <em>AG</em> as at March 31, 2024\n\n<em>BB</em> <em>Biotech</em> presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates\n\nInvestor sentiment in the biotech space continues to be shaped by the general interest rate environment.",
"sentiment": 0.765,
"highlighted_in": "main_text"
},
{
"highlight": "Nevertheless, for <em>BB</em> <em>Biotech</em> investors, the first quarter of 2024 ended with a pleasing performance of 11.3% in CHF and 7.6% in EUR including the dividend payout of CHF 2.00 per share. The portfolio's total return (NAV) stood at 11.2% in CHF, 6.3% in EUR, and 3.8% in USD, which was slightly ahead of BB Biotech’s benchmark.",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "The <em>BB</em> <em>Biotech</em> share achieved a positive quarterly return of 11.3% in CHF and 7.6% in EUR, inclusive of a dividend payment of CHF 2.00 per share. The portfolio's total return was 11.2% in CHF, 6.3% in EUR, and 3.8% in USD, surpassing the NBI Index. The devaluation of the Swiss franc gave the portfolio a strong boost in the first quarter of 2024.",
"sentiment": 0.9186,
"highlighted_in": "main_text"
},
{
"highlight": "<em>BB</em> <em>Biotech</em> engaged in capital increases for Celldex and Esperion. Further portfolio enhancements involved additions to Sage and Generation Bio, and profits from Crispr Therapeutics were reallocated to Beam Therapeutics.\n\nPortfolio milestones for the first quarter 2024\n\nBiotech markets remained volatile during the first quarter of 2024.",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "Gallen, Switzerland, tel. +41 79 423 22 28\n\nThomas Egger, [email protected]\n\nwww.bbbiotech.com\n\nCompany profile\n\n<em>BB</em> <em>Biotech</em> <em>AG</em> is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss and German stock exchanges.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>BB</em> <em>Biotech</em> is one of the world’s largest investors in this sector. The competent Board of Directors with its long-standing experience set the investment strategy and guidelines. Investment decisions are taken by the experienced investment management team of Bellevue Asset Management AG based on their extensive investment research.",
"sentiment": 0.5859,
"highlighted_in": "main_text"
},
{
"highlight": "Such statements are based on the current expectations of <em>BB</em> <em>Biotech</em>, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, <em>BB</em> <em>Biotech</em> and its directors and officers accept no responsibility in that regard.",
"sentiment": -0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "All forward-looking statements included in this release are made only as of the date of this release and <em>BB</em> <em>Biotech</em> and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.",
"sentiment": -0.296,
"highlighted_in": "main_text"
},
{
"highlight": "<em>BB</em> <em>Biotech</em> presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates",
"sentiment": 0.5574,
"highlighted_in": "title"
}
]
},
{
"symbol": "ARGX.BR",
"name": "argenx SE",
"exchange": null,
"exchange_long": null,
"country": "be",
"type": "equity",
"industry": "Healthcare",
"match_score": 13.333668,
"sentiment_score": 0.296,
"highlights": [
{
"highlight": "Composition of BB Biotech’s portfolio as at March 31, 2024\n\n(in % of securities, rounded values)\n\nIonis Pharmaceuticals 11.4% <em>Argenx</em> <em>SE</em> 9.7% Neurocrine Biosciences 9.0% Vertex Pharmaceuticals 7.7% Intra-Cellular Therapies 6.2% Moderna 5.8% Revolution Medicines 5.2% Macrogenics 4.7% Alnylam Pharmaceuticals 4.3% Incyte 3.9% Celldex Therapeutics 3.7% Agios",
"sentiment": 0.296,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BION.SW",
"name": "BB Biotech AG",
"exchange": null,
"exchange_long": null,
"country": "ch",
"type": "equity",
"industry": "Healthcare",
"match_score": 68.13866,
"sentiment_score": 0.41254,
"highlights": [
{
"highlight": "EQS-News: <em>BB</em> <em>BIOTECH</em> <em>AG</em> / Key word(s): Interim Report\n\n<em>BB</em> <em>Biotech</em> presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates\n\n\n\n26.04.2024 / 07:00 CET/CEST\n\nThe issuer is solely responsible for the content of this announcement.",
"sentiment": 0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "Media release as at April 26, 2024\n\nPortfolio of <em>BB</em> <em>Biotech</em> <em>AG</em> as at March 31, 2024\n\n<em>BB</em> <em>Biotech</em> presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates\n\nInvestor sentiment in the biotech space continues to be shaped by the general interest rate environment.",
"sentiment": 0.765,
"highlighted_in": "main_text"
},
{
"highlight": "Nevertheless, for <em>BB</em> <em>Biotech</em> investors, the first quarter of 2024 ended with a pleasing performance of 11.3% in CHF and 7.6% in EUR including the dividend payout of CHF 2.00 per share. The portfolio's total return (NAV) stood at 11.2% in CHF, 6.3% in EUR, and 3.8% in USD, which was slightly ahead of BB Biotech’s benchmark.",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "The <em>BB</em> <em>Biotech</em> share achieved a positive quarterly return of 11.3% in CHF and 7.6% in EUR, inclusive of a dividend payment of CHF 2.00 per share. The portfolio's total return was 11.2% in CHF, 6.3% in EUR, and 3.8% in USD, surpassing the NBI Index. The devaluation of the Swiss franc gave the portfolio a strong boost in the first quarter of 2024.",
"sentiment": 0.9186,
"highlighted_in": "main_text"
},
{
"highlight": "<em>BB</em> <em>Biotech</em> engaged in capital increases for Celldex and Esperion. Further portfolio enhancements involved additions to Sage and Generation Bio, and profits from Crispr Therapeutics were reallocated to Beam Therapeutics.\n\nPortfolio milestones for the first quarter 2024\n\nBiotech markets remained volatile during the first quarter of 2024.",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "Gallen, Switzerland, tel. +41 79 423 22 28\n\nThomas Egger, [email protected]\n\nwww.bbbiotech.com\n\nCompany profile\n\n<em>BB</em> <em>Biotech</em> <em>AG</em> is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss and German stock exchanges.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>BB</em> <em>Biotech</em> is one of the world’s largest investors in this sector. The competent Board of Directors with its long-standing experience set the investment strategy and guidelines. Investment decisions are taken by the experienced investment management team of Bellevue Asset Management AG based on their extensive investment research.",
"sentiment": 0.5859,
"highlighted_in": "main_text"
},
{
"highlight": "Such statements are based on the current expectations of <em>BB</em> <em>Biotech</em>, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, <em>BB</em> <em>Biotech</em> and its directors and officers accept no responsibility in that regard.",
"sentiment": -0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "All forward-looking statements included in this release are made only as of the date of this release and <em>BB</em> <em>Biotech</em> and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.",
"sentiment": -0.296,
"highlighted_in": "main_text"
},
{
"highlight": "<em>BB</em> <em>Biotech</em> presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates",
"sentiment": 0.5574,
"highlighted_in": "title"
}
]
},
{
"symbol": "A1RG34.SA",
"name": "argenx SE",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 13.332367,
"sentiment_score": 0.296,
"highlights": [
{
"highlight": "Composition of BB Biotech’s portfolio as at March 31, 2024\n\n(in % of securities, rounded values)\n\nIonis Pharmaceuticals 11.4% <em>Argenx</em> <em>SE</em> 9.7% Neurocrine Biosciences 9.0% Vertex Pharmaceuticals 7.7% Intra-Cellular Therapies 6.2% Moderna 5.8% Revolution Medicines 5.2% Macrogenics 4.7% Alnylam Pharmaceuticals 4.3% Incyte 3.9% Celldex Therapeutics 3.7% Agios",
"sentiment": 0.296,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "4bb2f1cd-2474-4921-9cbd-a7251329b91b",
"title": "Stephens cuts Hub Group shares target on extended freight downcycle outlook By Investing.com",
"description": "Stephens cuts Hub Group shares target on extended freight downcycle outlook",
"keywords": "",
"snippet": "On Friday, Stephens has adjusted its price target for Hub Group (NASDAQ: NASDAQ: ) shares, a supply chain solutions and logistics company, to $42.00 from the pr...",
"url": "https://www.investing.com/news/company-news/stephens-cuts-hub-group-shares-target-on-extended-freight-downcycle-outlook-93CH-3400413",
"image_url": "https://i-invdn-com.investing.com/news/World_News_8_800x533_L_1420026210.jpg",
"language": "en",
"published_at": "2024-04-26T11:02:30.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "HUBG",
"name": "Hub Group, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 22.177395,
"sentiment_score": 0.4215,
"highlights": [
{
"highlight": "See disclosureor\n\nInvestingPro Insights\n\nAs Hub Group (<em>NASDAQ</em>: <em>HUBG</em>) navigates through a challenging freight down-cycle, real-time data and insights from InvestingPro could provide investors with a more nuanced understanding of the company's financial health and future prospects.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "NASDAQ",
"total_documents": 1908,
"sentiment_avg": 0.27168867112020556
}
]
}
Other details
Country
- us
- 5,275